Application of E3 ubiquitin ligase CHIP or coding gene thereof in preparation of anti-hepatitis E virus drugs

By delivering E3 ubiquitin ligase CHIP in cells to reduce the ORF1 protein level of HEV, the shortcomings of the treatment of hepatitis E virus infection in the prior art are solved, effective inhibition of viral replication is achieved, and targeting low immune function and potential treatment options for pregnant women.

CN118903395APending Publication Date: 2024-11-08ZJU HANGZHOU GLOBAL SCI & TECH INNOVATION CENT
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410966300.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-17
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

The prior art lacks effective targeted therapies for hepatitis E virus (HEV) infection, especially for immunocompromised populations and pregnant women, and broad-spectrum antiviral drugs are ineffective in 20%-30% of patients and may lead to viruses. Drug resistance mutations.

Method used

The E3 ubiquitin ligase CHIP or its encoding gene is used to deliver it to infected cells through vectors, and its ubiquitin ligase activity reduces the level of the non-structural protein ORF1 protein of HEV, thereby inhibiting viral replication.

Benefits of technology

It effectively reduced the ORF1 protein level of HEV, significantly inhibited viral replication, and demonstrated the potential therapeutic effect against hepatitis E virus.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118903395A_ABST
    Figure CN118903395A_ABST
Patent Text Reader

Abstract

The invention discloses an application of E3 ubiquitin ligase CHIP or a coding gene thereof in preparation of an anti-hepatitis E virus drug. Research finds that E3 ubiquitin ligase CHIP can be combined with and degrade non-structural protein ORF1 of HEV, regulation of CHIP on ORF1 depends on activity of the ubiquitin ligase, CHIP protein expression in cells is reduced, and HEV replication is remarkably promoted. The E3 ubiquitin ligase CHIP and the coding gene thereof have the potential of being developed into anti-hepatitis E virus drugs.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biomedicine technology, and specifically relates to the application of E3 ubiquitin ligase CHIP or its encoding gene in the preparation of anti-hepatitis E virus drugs. Background Art

[0002] Hepatitis E virus (HEV) infection is an important factor causing human viral hepatitis. Immunocompromised people have a 60% chance of developing chronic HEV infection, and 10% of chronically infected patients will develop cirrhosis within 2 years. In addition, pregnant women infected with HEV genotype 1 can suffer from serious consequences such as fulminant hepatic failure, massive bleeding and stillbirth, with a mortality rate of up to 30% ([1] Nimgaonkar, I., Ding, Q., Schwartz, RE & Ploss, A. Hepatitis E virus: advances and challenges. Nat Rev Gastroenterol Hepatol 15, 96-110, doi: 10.1038 / nrgastro.2017.150 (2018). [2] Khuroo, MS & Khuroo, MS Hepatitis E: an emerging global disease-from discovery towards control and cure. J Viral Hepat 23, 68-79, doi: 10.1111 / jvh.12445 (2016).).

[0003] Currently, there is no specific therapy targeting HEV, nor is there a treatment suitable for pregnant women and immunocompromised patients. For HEV infection, the main clinical treatments are the broad-spectrum antiviral drugs ribavirin and interferon α (IFNα). However, these drugs are ineffective for 20%-30% of patients, and long-term use of nucleoside analogs can easily lead to drug-resistant mutations in the virus.

[0004] HEV is a single-stranded positive-strand RNA virus with a virus particle size of about 27-32nm and a regular icosahedral structure. Its capsid is a single-layer protein structure formed by self-assembly. The genome size of HEV is about 7.2kb, containing three open reading frames (ORFs), which encode a non-structural protein (ORF1) with a molecular weight of about 190kDa responsible for virus replication, a capsid protein (ORF2), and a protein related to virus release (ORF3). Among them, ORF1 protein is the decisive protein in the life cycle of HEV virus (Zhang, F.eta1.Targeting proteostasis of the HEV replicase to combat infection in preclinical models.J Hepatol, doi: 10.1016 / j.jhep.2022.12.010(2022).). Therefore, targeted degradation of ORF1 protein can inhibit the replication of HEV virus and treat diseases caused by HEV virus infection. Summary of the invention

[0005] In view of the above-mentioned deficiencies in the prior art, the present invention provides the use of E3 ubiquitin ligase CHIP or its encoding gene in the preparation of anti-hepatitis E virus drugs.

[0006] Application of E3 ubiquitin ligase CHIP or its encoding gene in the preparation of anti-hepatitis E virus drugs.

[0007] Preferably, the E3 ubiquitin ligase CHIP is of human or mouse origin, and the amino acid sequence of the mouse E3 ubiquitin ligase CHIP is shown in SEQ ID No.1; the amino acid sequence of the human E3 ubiquitin ligase CHIP is shown in SEQ ID No.13.

[0008] Preferably, the encoding gene sequence of mouse E3 ubiquitin ligase CHIP is shown as SEQ ID No.2; the encoding gene sequence of human E3 ubiquitin ligase CHIP is shown as SEQ ID No.14.

[0009] The coding gene sequence of human E3 ubiquitin ligase CHIP has a high homology with that of mouse, approaching 90%.

[0010] Preferably, the gene encoding the E3 ubiquitin ligase CHIP is delivered to cells infected with hepatitis E virus via a vector to exert its effect. The vector is an adenovirus, adeno-associated virus, lentivirus or plasmid.

[0011] Preferably, the E3 ubiquitin ligase CHIP exerts its effect by intravenous injection or in situ injection into the liver.

[0012] Preferably, the E3 ubiquitin ligase CHIP acts by reducing the level of ORF1 protein of hepatitis E virus.

[0013] Preferably, the E3 ubiquitin ligase CHIP has ubiquitin ligase activity.

[0014] The present invention found that E3 ubiquitin ligase CHIP can bind to and degrade the non-structural protein ORF1 of HEV. The regulation of ORF1 by CHIP depends on its ubiquitin ligase activity. Reducing the expression of CHIP protein in cells significantly promotes the replication of HEV. E3 ubiquitin ligase CHIP and its encoding gene have the potential to be developed as anti-hepatitis E virus drugs. BRIEF DESCRIPTION OF THE DRAWINGS

[0015] Figure 1 This is the result of the interaction detection between HEV ORF1 protein and CHIP.

[0016] Figure 2 This is the result of CHIP-mediated HEV ORF1 protein degradation detection, where: Figure 2 A in the figure is the result of plasmid expressing CHIP-HA with increasing dose gradient; Figure 2 B in the figure is the comparison result of the point mutation CHIP-HA (H260Q).

[0017] Figure 3 This is a diagram showing the detection results of CHIP-mediated ubiquitination modification of ORF1 protein.

[0018] Figure 4 This is the result of the detection that knocking down CHIP promotes HEV replication, where: Figure 4 A in the figure is HEV replicon cell S10-3-EZ; Figure 4 B in the figure represents wild-type S10-3 cells. DETAILED DESCRIPTION

[0019] The present invention is described in detail below by specific examples. It is pointed out that the following examples are only used to further illustrate the present invention and cannot be understood as limiting the scope of protection of the present invention. Those skilled in the art can make some non-essential improvements and adjustments to the present invention based on the above invention content. The raw materials and reagents used in the present invention are all commercially available products.

[0020] The amino acid sequence of E3 ubiquitin ligase CHIP is shown in SEQ ID No. 1. The coding gene sequence of E3 ubiquitin ligase CHIP is shown in SEQ ID No. 2.

[0021] The ORF1 gene sequence of HEV is shown in SEQ ID No.3.

[0022] Example 1: HEV ORF1 protein interacts with CHIP

[0023] 1. Plasmids and cells for ORF1 protein expression

[0024] Human embryonic kidney HEK293 cells were transfected with the Myc-tagged ORF1 plasmid to construct cells overexpressing ORF1 protein.

[0025] Construction of Myc-tagged ORF1 plasmid (ORF1-Myc plasmid): vector pRK5, restriction site front XbaI, rear HindIII. ORF1 was amplified from a cDNA plasmid containing the full-length genome of genotype 3 (Kernow-C1p6) HEV (gift from Dr. Suzanne U. Emerson of NIH; GenBank No. JQ679013).

[0026] Plasmid construction process:

[0027] 1. Primer Design

[0028] Forward primer ORF1-F-XbalI (shown in SEQ ID No.4):

[0029] GCTCTAGAACCATGGAGGCCCACCAGTTCATTAA;

[0030] Reverse primer ORF1-R-HindIII-Myc (as shown in SEQ ID No.5):

[0031] CCAAGCTTTCACAGATCCCTTCAGAGATGAGTTTCTGCTCTTCTACCCGCTGTATGATGG.

[0032] 2. PCR amplification of target gene fragments

[0033] The dry powdered primers synthesized by the entrusted company were diluted to 10 μM with ddH2O, and the target gene was amplified using NEB's Q5 Ultra-Fidelity 2× Master Mix. The specific operations were carried out according to the instructions.

[0034] This time, a 50 μl reaction system was used, 100 ng of ORF1 template plasmid, 55 degrees annealing temperature, and 30 cycles were set.

[0035] 3. Purify the amplified target gene fragment

[0036] Prepare 8% agarose gel, load the sample and run the gel, set the parameters to constant voltage 200V, time 20min. After running the gel, refer to the Maker under UV light, select the band of the correct size for gel cutting, weigh it, and use the Axygen gel recovery kit for gel recovery.

[0037] 4. Enzyme digestion and purification of target gene fragments and vectors

[0038] Enzyme digestion conditions: 16 degrees, 4h.

[0039] (1) Fragment digestion (50 μl system)

[0040]

[0041] (2) Vector digestion (20 μl system)

[0042]

[0043] 5. After the restriction digestion, the target gene fragment is recovered using Axygen's PCR cleaning kit. The vector plasmid after the restriction digestion is recovered by gel, and the steps are the same as step 3 above.

[0044] 6. Ligation of target gene fragment and vector

[0045] Use NEB's T4 DNA ligase in a 20 μl system.

[0046]

[0047] 7. Enzyme-linked product transformation plate

[0048] (1) Take competent E. coli top10 and mark the name of the transferred enzyme-linked product. (2) Take 5μl of the enzyme-linked product and add it to the competent E. coli tube. After adding, use your fingers to flick the bottom of the tube a few times. (3) Let it stand on ice for 15-20 minutes, put it in a 42-degree water bath for 45-90 seconds, and then put it on ice for 3 minutes. (4) Use a gun to suck up the liquid in the tube, add it to the plate, and use a sterile iron rod to spread it evenly. (6) Incubate it in a 37-degree incubator overnight.

[0049] 8. Bacteria selection and expression detection

[0050] Two monoclonal colonies with good growth were selected from each plate for shaking, and then sent to the company for sequencing. After sequencing verification, the plasmid pRK5-ORF1-Myc overexpressing ORF1 protein was obtained. The plasmid was extracted and expression was detected in HEK293 cells to obtain cells overexpressing ORF1 protein.

[0051] 2. Plasmids and cells for CHIP protein expression

[0052] CHIP-HA plasmid information: vector pRK5-3×HA (i.e., pRK5 vector contains sequences encoding three HA tags), restriction sites are BamHI at the front and SalI at the back. CHIP was amplified from a cDNA plasmid containing the CHIP (NM 019719.3, also known as STUB1) gene (purchased from SinoBiological Inc. (Beijing, China), Cat: MG53743-UT).

[0053] PCR Primers:

[0054] Forward primer CHIP-F-BamHI (shown in SEQ ID No.6):

[0055] CGGGATCACCATGAAGGGCAAGGAGGAAAAGG;

[0056] Reverse primer CHIP-R-SalI-HA (as shown in SEQ ID No.7):

[0057] GCGTCGACATAGTCCTCTACCCAGCCGTTC.

[0058] The other steps are the same as those for constructing the ORF1-Myc expression plasmid.

[0059] 3. Interaction Detection

[0060] After the cells overexpressing ORF1 protein were lysed, immunoprecipitation was performed using Myc antibody, protein-antibody complexes were enriched using ProteinA magnetic beads, and then SDS-PAGE electrophoresis was performed. After gel cutting, mass spectrometry was used for detection and analysis.

[0061] Cell lysis buffer (Myc lysis buffer (MLB)): 20 mM Tris-HCl, 200 mM NaCl, 10 mM NaF, 1 mM NaV2O4, 1% NP-40, 20 mM β-glycerophosphate, protease inhibitor, pH 7.5.

[0062] In the data analysis, we found that the E3 ubiquitin ligase CHIP had a significant interaction with the viral ORF1 protein.

[0063] The mass spectrometry data are shown in Table 1.

[0064] Table 1

[0065]

[0066] To verify the results of the mass spectrometry experiment, we transfected 500 ng of plasmids expressing ORF1-Myc protein and 500 ng of plasmids expressing CHIP-HA protein into HEK293 cells, and found that they had a strong interaction by co-immunoprecipitation. Figure 1 shown.

[0067] Interaction detection experimental method:

[0068] (1) HEK293 cells were divided into six-well plates at a density of 50%, and plasmid transfection was performed 6 hours later, including 500 ng of CHIP-HA plasmid and 500 ng of ORF1-Myc plasmid. The medium was changed 4-6 hours after transfection, and the cells were harvested 24 hours later.

[0069] (2) Collect the cells, remove the culture medium, wash once with PBS, add 300 μl / well of MLB lysis buffer to the six-well plate, and lyse for 15 min on a 2D shaker in a 4°C refrigerator. Then, pipette all the lysis liquid into an EP tube and centrifuge at 12,000 r / min at 4°C for 15 min.

[0070] (3) After centrifugation, take 200 μl of the supernatant and place it in a new EP tube. Add 1 μl of the corresponding Myc antibody produced by CST at a ratio of 1:200, and incubate in a 3D shaker in a 4°C refrigerator. After incubation for 2 h, centrifuge the reaction solution EP tube, add 50 μl of beads to each sample, and then incubate in a 3D shaker in a 4°C refrigerator for 1 h.

[0071] (4) After incubation, centrifuge at 5000r / min at 4°C for 90s, remove the supernatant, add 1ml MLB, and then incubate on a 3D shaker in a 4°C refrigerator for 5min. Repeat twice. Finally, remove the supernatant and add 32μl 2×Sample buffer to prepare the gel sample.

[0072] (5) The expression and interaction of each plasmid were detected by immunoblotting experiments.

[0073] Example 2: CHIP mediates HEV ORF1 protein degradation

[0074] The same amount of plasmid expressing ORF1 protein (50 ng) and increasing doses of plasmid expressing CHIP-HA (0, 50 ng, 200 ng, 400 ng) were co-transfected into HEK293 cells.

[0075] The experimental results showed that CHIP reduced the level of ORF1 protein in a dose-dependent manner ( Figure 2 A).

[0076] To further explore whether the inhibitory effect of CHIP on ORF1 protein depends on its ubiquitin ligase activity, we used CHIP with the H260Q point mutation that has no ubiquitinase activity.

[0077] CHIP-H260Q-HA plasmid information: Using the vector CHIP-HA plasmid as a template, point mutations were introduced through PCR amplification mediated by specific primers.

[0078] (1) Design of PCR primers

[0079] Forward primer CHIP H260Q-F (as shown in SEQ ID No.8):

[0080] GGACATTGAGGAGCAGCTGCAGCGTGTGG;

[0081] Reverse primer CHIP H260Q-R (as shown in SEQ ID No.9):

[0082] CCACACGCTGCAGCTGCTCCTCAATGTCC.

[0083] (2) PCR amplification of target gene fragment

[0084] The dry powdered primers synthesized by the company were diluted to 10 μM with ddH2O, and the PCR reaction of the point mutation plasmid was performed using NEB's Q5 Ultra-Fidelity 2× Master Mix. The specific operation was carried out according to the instructions. This time, a 50 μl reaction system was used, 20 ng of CHIP-HA template plasmid, annealing temperature of 55 degrees, and 20 cycles were set.

[0085] (3) After PCR, add 1 μl of NEB's DPNI to digest the template at 37°C for 1 h.

[0086] (4) Subsequent steps such as transformation plating, shaking the bacteria, and sending for testing are the same as those for the above plasmid construction.

[0087] The experimental results showed that CHIP could reduce the protein level of ORF1, while the mutant protein CHIP-HA (H260Q) could not, indicating that the regulation of CHIP on ORF1 depends on its ubiquitin ligase activity ( Figure 2 B).

[0088] Example 3: CHIP-mediated ubiquitination of ORF1 protein

[0089] ORF1-Myc (500ng), K48-Ub-Flag (50ng, this plasmid is used to express Ub, and the expressed Ub has lysine 48, and all other lysine positions are mutated. This plasmid was kindly donated by Professor Xia Zongping of the Institute of Life Sciences, Zhejiang University) and CHIP-HA (50ng) plasmid (or point mutation plasmid CHIP-H260Q-HA (100ng)) were co-transfected into the HEK293 cell line. The effect of CHIP on the ubiquitination of ORF1 protein was detected by immunoprecipitation experiments. The experimental results showed that CHIP significantly promoted the K48 ubiquitination level of ORF1, and its ubiquitinase inactivation point mutation did not have this function. The results are as follows Figure 3 shown.

[0090] Example 4: Knockdown of CHIP promotes HEV replication

[0091] To investigate the effect of CHIP on HEV viral replication, we used three small interfering RNAs (siRNAs) specific for CHIP to downregulate the expression of endogenous CHIP in HEV replicon cells S10-3-EZ (i.e., human hepatoma cell line Huh7-EZ, see Chinese invention patent application publication number CN109913424A for details) and wild-type S10-3 cells (a subclone of Huh7, obtained from Dr. Suzanne U. Emerson (NIH, Bethesda, MD)).

[0092] The sequences corresponding to the three siRNAs are as follows:

[0093] siCHIP-1 (as shown in SEQ ID No. 10): CTGTGAAGGCGCACTTCTT, siCHIP-2 (as shown in SEQ ID No. 11): GCTCTTCGAATCGCGAAGA, siCHIP-3 (as shown in SEQ ID No. 12): AGCGCTGGAACAGCATTGA.

[0094] qRT-PCR revealed that these three siRNAs could effectively downregulate the mRNA level of CHIP in cells and significantly promote the level of HEV replicon in S10-3-EZ cells and viral replication in S10-3 cells infected with HEV. Figure 4 ( Figure 4 As shown in A and B).

Claims

1. Application of E3 ubiquitin ligase CHIP or its encoding gene in the preparation of anti-hepatitis E virus drugs.

2. The use according to claim 1, It is characterized in that The E3 ubiquitin ligase CHIP is of human or mouse origin. The amino acid sequence of the mouse E3 ubiquitin ligase CHIP is shown in SEQ ID No.1; the amino acid sequence of the human E3 ubiquitin ligase CHIP is shown in SEQ ID No.

13.

3. The use according to claim 1, It is characterized in that The coding gene sequence of mouse E3 ubiquitin ligase CHIP is shown in SEQ ID No.2; the coding gene sequence of human E3 ubiquitin ligase CHIP is shown in SEQ ID No.

14.

4. The use according to claim 1 or 3, It is characterized in that The gene encoding the E3 ubiquitin ligase CHIP is delivered into cells infected with the hepatitis E virus through a vector to exert its effect.

5. The use according to claim 4, It is characterized in that The vector is adenovirus, adeno-associated virus, lentivirus or plasmid.

6. The use according to claim 1 or 2, It is characterized in that The E3 ubiquitin ligase CHIP exerts its effect by intravenous injection or in situ injection into the liver.

7. The use according to claim 1, It is characterized in that The E3 ubiquitin ligase CHIP acts by reducing the level of ORF1 protein of HEV.

8. The use according to claim 1, It is characterized in that The E3 ubiquitin ligase CHIP has ubiquitin ligase activity.